Sarepta Therapeutics (SRPT) Stock Price, Quote & News

Company Profile

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dyst...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 274 4000

Website: www.sarepta.com

Address:

215 First Street, Suite 415, Cambridge, United States

Thaigrlsrk Mar. 22 at 12:32 AM

$SRPT Two thing from Cowen: Ian should berthe next CEO, and correct me if i am wrong , Sarepta is out to prove( Dm1) they are getting the most action in muscle and that will get the most knockdown and that is what their data will show- most in the muscle.

0 · Reply

Thaigrlsrk Mar. 21 at 11:59 PM

$SRPT Interesting sarepta is working on a trim platform/PMO combination. Learn something every day.

0 · Reply

Thaigrlsrk Mar. 21 at 11:52 PM

$SRPT Ian Estepan, President and COO, Sarepta: You know, I think knockdown and proof of concept from a functional measure, whoever has the highest knockdown will ultimately get the most share.

0 · Reply

Thaigrlsrk Mar. 21 at 11:49 PM

$SRPT Ebveruone should read this transcript: https://www.investing.com/news/transcripts/sarepta-at-td-cowen-conference-strategic-growth-and-challenges-93CH-4539891

0 · Reply

Thaigrlsrk Mar. 21 at 11:47 PM

$SRPT Says it all for DM1, Ian already knows what they have when he's talking here: DM1 data is going to be good and the comparator to DYNE is better: it will lead to the best clinical outcome. With all that being said, going back to your question, you know, what we’re looking for, it’s very low doses, what we’re looking for is a dose response curve from a muscle concentration perspective, from a PK perspective. Ritu Baral, Analyst, TD Cowen: Mm-hmm Ian Estepan, President and COO, Sarepta: to see, because this is the big question, is with using the TRiM platform and the siRNA approach, can we get more into. Ritu Baral, Analyst, TD Cowen: More into the muscle.

0 · Reply

Fred_Sigma_Invest Mar. 21 at 11:06 PM

$SRPT https://www.fool.com/investing/2026/03/21/2-beaten-down-stocks-that-still-arent-worth-buying/?source=quotemedia&utm_source=marketwirenew&utm_medium=feed&utm_campaign=article&referring_guid=89aa6802-ad72-45b2-99c4-f9768d4fb723

1 · Reply

LewisDaKat Mar. 21 at 9:00 PM

$SRPT 2 Beaten-Down Stocks That Still Aren't Worth Buying https://marketwirenews.com/stock/srpt/news/2-beaten-down-stocks-that-still-aren-t-worth-buying-5363046344819305.html?utm_source=stocktwits

1 · Reply

GordonBone Mar. 21 at 7:25 PM

$SRPT it’s not about who might work anymore. It’s about who’s already in real patients, showing real outcomes, year after year. Sarepta isn’t a theory anymore. It’s already happening!

0 · Reply

GordonBone Mar. 21 at 7:16 PM

$SRPT ENDEAVOR Cohort 8 kicking off for non-amb patients with a cleaner immunosuppression setup. Feels like they actually learned from the 2025 safety issues and fixed what mattered. Non-amb is a big untapped market too. Guidance looks solid and fundamentals still there...holding tight

1 · Reply

PaixTrader Mar. 21 at 7:02 PM

$SRPT This is single-dose (30/90d biopsy) vs peers DYN and RNA showing numbers largely from multi-dose cohorts. Single dose typically ≈ 50–70% of steady-state effect. So if SRPT shows: • ~25–30% , that could translate to ~40–50% with repeat dosing (competitive) • ~20–25% → gray zone (needs strong dose response) • <20% → likely behind The risk is apples-to-oranges comp vs multi-dose peer data . But what actually matters is clean dose response, consistency, and safety at higher doses. Bottom line is this readout = proof of mechanism, not peak efficacy. If biology works, numbers can scale with repeat dosing. If we clear 30% for early knockdown data for example, that would be very good. Stock initial reaction in 25-30% more tricky but should resolve nicely upwards after analysts release updated reports. If we are in the 40%+ range, we are going pie into the sky, and imo that gives very high probability to SRP1003 as best in class.

2 · Reply

Sarepta To Request FDA For Traditional Approvals For Duchenne Drugs

Mar 19, 2026, 8:30 AM EDT - 2 days ago

Sarepta Provides Regulatory Update on AMONDYS 45® and VYONDYS 53®

Mar 16, 2026, 8:33 AM EDT - 5 days ago

Sarepta Announces that Screening and Enrollment are Underway in ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Mar 3, 2026, 5:32 PM EST - 18 days ago

Sarepta Therapeutics, Inc. (SRPT) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Feb 27, 2026, 9:00 AM EST - 22 days ago

Sarepta Therapeutics Announces Call for Applications for the 9th Annual Route 79, The Duchenne Scholarship Program

Feb 26, 2026, 8:30 AM EST - 23 days ago

Sarepta Therapeutics to Present New Long-Term and Safety Data Across Gene Therapy and Exon-Skipping Programs at 2026 Muscular Dystrophy Association Clinical & Scientific Congress

Feb 26, 2026, 5:52 AM EST - 23 days ago

Sarepta CEO To Jump Ship After 'Tumultuous' Year

Feb 26, 2026, 5:05 AM EST - 23 days ago

Sarepta Therapeutics CEO Ingram to retire by year end

Feb 25, 2026, 8:27 PM EST - 23 days ago

Sarepta Therapeutics, Inc. (SRPT) Q4 2025 Earnings Call Transcript

Feb 25, 2026, 4:05 PM EST - 24 days ago

Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments

Feb 24, 2026, 9:07 AM EST - 25 days ago

Sarepta Therapeutics Announces Commercial Launch of ELEVIDYS in Japan

Feb 24, 2026, 8:30 AM EST - 25 days ago

Sarepta Therapeutics to Present at the TD Cowen 46th Annual Health Care Conference

Feb 11, 2026, 8:30 AM EST - 5 weeks ago

Sarepta Therapeutics to Announce Fourth Quarter and Full-Year 2025 Financial Results

Feb 4, 2026, 8:30 AM EST - 6 weeks ago

Sarepta Therapeutics Announces Approval of Clinical Trial Application for SRP-1005, Its Investigational Treatment for Huntington's Disease

Jan 26, 2026, 1:32 PM EST - 7 weeks ago

Sarepta Therapeutics, Inc. (SRPT) Discusses 3-Year Topline Results From EMBARK Phase 3 Trial of ELEVIDYS in Duchenne Muscular Dystrophy Transcript

Jan 26, 2026, 8:53 AM EST - 7 weeks ago

Sarepta Stock Rises on Positive 3-Year Study Results for Elevidys

Jan 26, 2026, 8:10 AM EST - 7 weeks ago

Sarepta's Duchenne gene therapy helps maintain motor function, three-year data shows

Jan 26, 2026, 8:00 AM EST - 7 weeks ago

Sarepta Announces Positive Topline Three-Year EMBARK Results Showing ELEVIDYS Significantly Slows Disease Progression on Key Functional Measures in Ambulatory Duchenne Patients

Jan 23, 2026, 4:05 PM EST - 2 months ago

Sarepta Therapeutics to Report 3-Year Topline Data from EMBARK Study of ELEVIDYS Gene Therapy in Ambulatory Individuals with Duchenne Muscular Dystrophy

Jan 16, 2026, 9:25 AM EST - 2 months ago

Sarepta Therapeutics: Is Elevidys A Bust?

Jan 12, 2026, 2:36 PM EST - 2 months ago

Sarepta Therapeutics, Inc. (SRPT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

Jan 12, 2026, 11:58 AM EST - 2 months ago

Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues

Jan 12, 2026, 9:30 AM EST - 2 months ago

Johnson Fistel Investigates Sarepta Therapeutics, Inc. (SRPT) Directors for Potential Breaches of Fiduciary Duty

Jan 7, 2026, 8:30 AM EST - 2 months ago

Sarepta Therapeutics Announces Submission of Clinical Trial Application for SRP-1005, its Investigational Treatment for Huntington's Disease

Jan 5, 2026, 8:30 AM EST - 2 months ago

Sarepta Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Dec 31, 2025, 5:20 PM EST - 2 months ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 17, 2025, 6:48 AM EST - 3 months ago

Sarepta Therapeutics: Why The Newborn Screening Decision For DMD Matters More Than The Stock Move Suggests

Dec 11, 2025, 7:00 AM EST - 3 months ago

Sarepta Therapeutics Announces Refinancing of Approximately $291 Million of 1.25% Convertible Senior Notes due 2027

Nov 25, 2025, 12:07 PM EST - 4 months ago

Sarepta Secures FDA Nod For Elevidys Study To Reduce Liver Injury Risk

Nov 25, 2025, 8:57 AM EST - 4 months ago

Sarepta Announces Approval to Begin ENDEAVOR Cohort 8 to Evaluate Enhanced Immunosuppression Regimen as Part of ELEVIDYS Gene Therapy for Non-Ambulant Individuals with Duchenne

Nov 24, 2025, 7:30 AM EST - 4 months ago

Arrowhead Pharmaceuticals Earns $200 Million Milestone Payment from Sarepta Therapeutics

ARWR

Nov 24, 2025, 7:30 AM EST - 4 months ago

Sarepta Provides Progress Update for SRP-1003, its Investigational siRNA treatment for Myotonic Dystrophy Type 1

Nov 14, 2025, 5:48 PM EST - 4 months ago

Sarepta Shares Jump After FDA Approves Updated Elevidys Label

Nov 14, 2025, 2:54 PM EST - 4 months ago

Sarepta Announces FDA's Approval of Updated ELEVIDYS Prescribing Information

Nov 14, 2025, 2:08 PM EST - 4 months ago

US FDA adds strongest warning to Sarepta gene therapy after fatal liver injuries

Nov 4, 2025, 1:39 PM EST - 4 months ago

Sarepta Therapeutics: Why High Risk, Low Return Until Mid-To-Late 2026

Nov 4, 2025, 12:33 PM EST - 4 months ago

Sarepta Faces Investor Skepticism As Duchenne Data Falls Short Of Statistical Significance

Nov 4, 2025, 12:11 PM EST - 4 months ago

Sarepta Stock Dumps: Pharma Bro Martin Shkreli Still Likes It

Nov 4, 2025, 9:55 AM EST - 4 months ago

Sarepta Therapeutics shares plunge after disappointing trial data

Nov 4, 2025, 6:20 AM EST - 4 months ago

Sarepta Stock Tumbles 40%. Why the Biotech's Shares Are Sinking.

Nov 4, 2025, 5:36 AM EST - 4 months ago

Sarepta Therapeutics, Inc. (SRPT) Q3 2025 Earnings Call Transcript

Nov 4, 2025, 4:27 AM EST - 4 months ago

Sarepta slumps as gene therapy setback adds to drug pipeline woes

Nov 3, 2025, 6:26 PM EST - 4 months ago

Sarepta's stock plummets as disappointing trial data raise questions on DMD drug's success

Nov 3, 2025, 4:24 PM EST - 4 months ago

Sarepta's Duchenne gene therapy misses main goal in study

Nov 3, 2025, 4:05 PM EST - 4 months ago

Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE

Oct 27, 2025, 4:05 PM EDT - 5 months ago

Sarepta Therapeutics to Announce Third Quarter 2025 Financial Results

Oct 23, 2025, 6:46 AM EDT - 5 months ago

Tradr Debuts Leveraged ETFs on BLSH, DASH, FLY, IREN, NEM, OPEN, QS, SRPT & WULF

BLSH DASH FLY IREN NEM OPEN QS

Oct 10, 2025, 11:49 AM EDT - 5 months ago

Sarepta Therapeutics: A Discounted Valuation Meets Breakthrough Pipeline

Oct 8, 2025, 11:19 AM EDT - 5 months ago

What's Going On Sarepta Stock On Wednesday?

Thaigrlsrk Mar. 22 at 12:32 AM

0 · Reply

Thaigrlsrk Mar. 21 at 11:59 PM

$SRPT Interesting sarepta is working on a trim platform/PMO combination. Learn something every day.

0 · Reply

Thaigrlsrk Mar. 21 at 11:52 PM

$SRPT Ian Estepan, President and COO, Sarepta: You know, I think knockdown and proof of concept from a functional measure, whoever has the highest knockdown will ultimately get the most share.

0 · Reply

Thaigrlsrk Mar. 21 at 11:49 PM

$SRPT Ebveruone should read this transcript: https://www.investing.com/news/transcripts/sarepta-at-td-cowen-conference-strategic-growth-and-challenges-93CH-4539891

0 · Reply

Thaigrlsrk Mar. 21 at 11:47 PM

0 · Reply

Fred_Sigma_Invest Mar. 21 at 11:06 PM

1 · Reply

LewisDaKat Mar. 21 at 9:00 PM

$SRPT 2 Beaten-Down Stocks That Still Aren't Worth Buying https://marketwirenews.com/stock/srpt/news/2-beaten-down-stocks-that-still-aren-t-worth-buying-5363046344819305.html?utm_source=stocktwits

1 · Reply

GordonBone Mar. 21 at 7:25 PM

$SRPT it’s not about who might work anymore. It’s about who’s already in real patients, showing real outcomes, year after year. Sarepta isn’t a theory anymore. It’s already happening!

0 · Reply

GordonBone Mar. 21 at 7:16 PM

1 · Reply

PaixTrader Mar. 21 at 7:02 PM

2 · Reply

nopennys Mar. 21 at 6:31 PM

$SRPT what happened here just at market close yesterday? Huge volume?

1 · Reply

Wolfman5960 Mar. 21 at 6:12 PM

$SRPT For those waiting for the DM1 and FSHD data drop I recommend listening to the TD Cowen Conference with Ian Estepan on March 3rd (Discussion starts at the 16:45 min mark). They mentioned that data drop is still on track by the end of Q1 and Ian discusses what doses to expect from this drop at the 20:40 min mark. Looks like for DM1 it'll be the 1.5 mg/kg and 3 mg/kg data and for FSHD Ian said it will be the 1 mg/kg (I think he meant 1.5 mg/kg, but he said 1), 3 mg/kg, and 6 mg/kg . These are all from the single dose cohorts with biopsies at 30 days and 90 days.

0 · Reply

iCro93 Mar. 21 at 3:47 PM

$SRPT we should all buy some shares at Monday open -> only on red candles. Doesn’t matter how much you buy, buy the red candles. Set an order at 100$ for the ask, the more we are the higher is the pressure on the ask once this goes parabolic with news. Just my thoughts, buy shares instead of calls.

0 · Reply

Dont_believe_pumper Mar. 21 at 11:47 AM

$SRPT when will SRPT sign the deal ?? Roche, Nvidia’s 'AI Factory' The AI race in biopharma is heating up. Roche and Nvidia partnered on what they’re calling the "largest announced hybrid-cloud AI factory" in the industry. The announcement comes just a few months after Eli Lilly unveiled plans for its own AI-powered supercomputer, which Lilly claimed would be biopharma’s most powerful. Roche’s Genentech originally signed a deal with Nvidia in 2023. The newly expanded agreement covers the broader Roche enterprise, spanning its drugs and diagnostics businesses and areas like discovery, manufacturing and sales. The computing power will be used to train and run AI models across those functions. On the hardware side, Roche is adding 2,716 of Nvidia's Blackwell GPUs, bringing its total to over 3,500 Blackwell chips — compared with the 1,016 chips in Lilly's supercomputer. Biopharma industry looks to soften MFN i

1 · Reply

GhostInTheStocks Mar. 21 at 11:03 AM

$SRPT if you are panic selling your shares during the large dips these past six months, it is likely that some of them are ending up in blackrock or vanguard hands. They have been the biggest dip buyers, blackrock being the more agressive buyer.

0 · Reply

HuanLee Mar. 21 at 7:21 AM

$SRPT Not just a drug… this is a whole modality shift playing out in real time

0 · Reply

HillA Mar. 21 at 6:11 AM

$SRPT Every update = more validation the science works. That’s what matters long term.

0 · Reply

iceicemoney10 Mar. 21 at 4:24 AM

$SRPT gentleman, I don’t know any of you fellow bulls. I’m hammered at the club. I feel like we are all a brotherhood, fighting in the trenches together. We will prevail. Keep fighting the good fight. We will beat AF and the shorts and these families will get the treatments they deserve!!

0 · Reply

iceicemoney10 Mar. 21 at 3:47 AM

$SRPT Monday. We are rich gentleman. Enjoy the weekend. Get ready to print Monday fellas

1 · Reply

Thaigrlsrk Mar. 21 at 12:12 AM

$SRPT People act like it's an automatic thing RGNX or SLDB drugs will be better. It ain't. It is as likely they will have deaths as it is/was for Sarepta. Sarepta has in people data out to six years they only have very short time data and even that is questionably comparable. Long way to go to prove either.

0 · Reply

Thaigrlsrk Mar. 20 at 11:28 PM

$SRPT AF says ( and some others ) that the PMo's are just placebos. Billy one of the original 12 kids in the Etep( exon 51) trial is now in his 20's been on Etep for more then 10 years, he decided against Elevidys( nuts IMO but who am i to say) because he was happy with how he has held up on the PMO. FK AF and all those guys that bet against it's approval and lost . They lost because there is BENEFIT. EOS. He should interview people like Billy instead of running his mouth against the rare disease kids.

0 · Reply

DM73 Mar. 20 at 11:21 PM

$SRPT you thinking weekend / Monday?

2 · Reply

Market Cap	1.80B
Revenue (ttm)	2.20B
Net Income (ttm)	-713.41M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	6.14
Profit Margin	-32.45%
Debt to Equity Ratio	0.73

Volume	2,864,000
Avg Vol	2,658,566
Day's Range	N/A - N/A
Shares Out	104.99M
Stochastic %K	22%
Beta	0.42
Analysts	Sell
Price Target	$20.61